The company said its product is bioequivalent and therapeutically equivalent to ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), the reference listed drug of Provepharm SAS.
Citing IQVIA sales data, Glenmark noted that the ProvayBlue injection market recorded annual sales of about $19 million for the 12-month period ended April 2026.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “the launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.”
Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.
The company reported a 6,381.9% increase in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26, compared with Q4 FY25.
The counter fell 1.31% to Rs 2,128.50 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."